BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hsu CL, Ou DL, Bai LY, Chen CW, Lin L, Huang SF, Cheng AL, Jeng YM, Hsu C. Exploring Markers of Exhausted CD8 T Cells to Predict Response to Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma. Liver Cancer 2021;10:346-59. [PMID: 34414122 DOI: 10.1159/000515305] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Benesova K, Kraus FV, Carvalho RA, Lorenz H, Hörth CH, Günther J, Klika KD, Graf J, Diekmann L, Schank T, Christopoulos P, Hassel JC, Lorenz HM, Souto-Carneiro M. Distinct immune-effector and metabolic profile of CD8+ T cells in patients with autoimmune polyarthritis induced by therapy with immune checkpoint inhibitors. Ann Rheum Dis 2022:annrheumdis-2022-222451. [PMID: 35922125 DOI: 10.1136/ard-2022-222451] [Reference Citation Analysis]
2 Li J, Yu J, Zhang T, Pu X, Li Y, Wu Z. Genomic analysis quantifies pyroptosis in the immune microenvironment of HBV-related hepatocellular carcinoma. Front Immunol 2022;13:932303. [DOI: 10.3389/fimmu.2022.932303] [Reference Citation Analysis]
3 Yuan J, Zhao X, Li Y, Yao Q, Jiang L, Feng X, Shen L, Li Y, Chen Y. The Association between Blood Indexes and Immune Cell Concentrations in the Primary Tumor Microenvironment Predicting Survival of Immunotherapy in Gastric Cancer. Cancers (Basel) 2022;14:3608. [PMID: 35892867 DOI: 10.3390/cancers14153608] [Reference Citation Analysis]
4 Sun T, Zhou M, Huang L. Chimeric antigen receptor engineered T-cell therapy for central nervous system lymphoma. Hematology and Oncology Discovery 2022;1. [DOI: 10.15212/hod-2022-0001] [Reference Citation Analysis]
5 Bertuzzi C, Germinario G, Righi S, Ravaioli M, Agostinelli C, Pession A, D'Errico A, Sabattini E, Vasuri F. The role of peritumoral CD8 + /TIA1 + lymphocytes in hepatocellular carcinoma aggressiveness and recurrence after surgical resection. Pathol Res Pract 2022;237:154016. [PMID: 35872367 DOI: 10.1016/j.prp.2022.154016] [Reference Citation Analysis]
6 Jia W, Zhang T, Yao Q, Li J, Nie Y, Lei X, Mao Z, Wang Y, Shi W, Song W. Tertiary Lymphatic Structures in Primary Hepatic Carcinoma: Controversy Cannot Overshadow Hope. Front Immunol 2022;13:870458. [DOI: 10.3389/fimmu.2022.870458] [Reference Citation Analysis]
7 Kovács SA, Győrffy B. Transcriptomic datasets of cancer patients treated with immune-checkpoint inhibitors: a systematic review. J Transl Med 2022;20:249. [PMID: 35641998 DOI: 10.1186/s12967-022-03409-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Zhu M, Li X, Cheng X, Yi X, Ye F, Li X, Hu Z, Zhang L, Nie J, Li X. Association of the tissue infiltrated and peripheral blood immune cell subsets with response to radiotherapy for rectal cancer. BMC Med Genomics 2022;15:107. [PMID: 35534879 DOI: 10.1186/s12920-022-01252-6] [Reference Citation Analysis]
9 Su Y, Xu B, Shen Q, Lei Z, Zhang W, Hu T. LIMK2 Is a Novel Prognostic Biomarker and Correlates With Tumor Immune Cell Infiltration in Lung Squamous Cell Carcinoma. Front Immunol 2022;13:788375. [PMID: 35273591 DOI: 10.3389/fimmu.2022.788375] [Reference Citation Analysis]
10 Zhao Z, Wang Z, Wu Y, Liao D, Zhao B. Comprehensive analysis of TAMs marker genes in glioma for predicting prognosis and immunotherapy response. Molecular Immunology 2022;144:78-95. [DOI: 10.1016/j.molimm.2022.02.012] [Reference Citation Analysis]
11 Montironi C, Castet F, Haber PK, Pinyol R, Torres-Martin M, Torrens L, Mesropian A, Wang H, Puigvehi M, Maeda M, Leow WQ, Harrod E, Taik P, Chinburen J, Taivanbaatar E, Chinbold E, Solé Arqués M, Donovan M, Thung S, Neely J, Mazzaferro V, Anderson J, Roayaie S, Schwartz M, Villanueva A, Friedman SL, Uzilov A, Sia D, Llovet JM. Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification. Gut 2022:gutjnl-2021-325918. [PMID: 35197323 DOI: 10.1136/gutjnl-2021-325918] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
12 Hsieh CH, Jian CZ, Lin LI, Low GS, Ou PY, Hsu C, Ou DL. Potential Role of CXCL13/CXCR5 Signaling in Immune Checkpoint Inhibitor Treatment in Cancer. Cancers (Basel) 2022;14:294. [PMID: 35053457 DOI: 10.3390/cancers14020294] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Goggi JL, Ramasamy B, Tan YX, Hartimath SV, Tang JR, Cheng P, Msallam R, Chacko A, Hwang YY, Robins EG, Bogdanov A. Granzyme B PET Imaging Stratifies Immune Checkpoint Inhibitor Response in Hepatocellular Carcinoma. Molecular Imaging 2021;2021:1-8. [DOI: 10.1155/2021/9305277] [Reference Citation Analysis]
14 Zhu LR, Ni WJ, Cai M, Dai WT, Zhou H. Advances in RNA Epigenetic Modifications in Hepatocellular Carcinoma and Potential Targeted Intervention Strategies. Front Cell Dev Biol 2021;9:777007. [PMID: 34778277 DOI: 10.3389/fcell.2021.777007] [Reference Citation Analysis]
15 Capitani N, Patrussi L, Baldari CT. Nature vs. Nurture: The Two Opposing Behaviors of Cytotoxic T Lymphocytes in the Tumor Microenvironment. Int J Mol Sci 2021;22:11221. [PMID: 34681881 DOI: 10.3390/ijms222011221] [Reference Citation Analysis]
16 Pietrobon V, Todd LA, Goswami A, Stefanson O, Yang Z, Marincola F. Improving CAR T-Cell Persistence. Int J Mol Sci 2021;22:10828. [PMID: 34639168 DOI: 10.3390/ijms221910828] [Reference Citation Analysis]
17 Su YY, Li CC, Lin YJ, Hsu C. Adjuvant versus Neoadjuvant Immunotherapy for Hepatocellular Carcinoma: Clinical and Immunologic Perspectives. Semin Liver Dis 2021;41:263-76. [PMID: 34130338 DOI: 10.1055/s-0041-1730949] [Reference Citation Analysis]